Could Serum Sclerostin Help in Early Assessment and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder?

1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS One 2016; 11(7): e0158765.10.1371/journal.pone.0158765493490527383068Search in Google Scholar

2. Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease – mineral and bone disorder (CKD-MBD): Advances in pathophysiology. Bone 2017; 100: 80–86.10.1016/j.bone.2017.01.02328119179550271628119179Open DOISearch in Google Scholar

3. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267–6276.10.1093/emboj/cdg5991463398629184014633986Open DOISearch in Google Scholar

4. Figurek A, Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 2018; 50(10): 1863–1870.3003067710.1007/s11255-018-1935-530030677Search in Google Scholar

5. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248–255.10.1210/jc.2013-278624187403Search in Google Scholar

6. Sabbagh Y, Graciolli FG, O’Brien S, et al. Repression of osteocyte Wnt/-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone. Miner. Res. 2012; 27: 1757–177210.1002/jbmr.163022492547Open DOISearch in Google Scholar

7. Bielesz BO, Hempfing T, Kieweg H, et al. Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 2014; 38: 30–36.10.1159/00036499225228355Search in Google Scholar

8. Yamada S, Tsuruya K, Tokumoto M, et al. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 2015; 20: 639–645.10.1111/nep.1250925974190Search in Google Scholar

9. Desjardins L, Liabeuf S, Oliveira R.B, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-61.Search in Google Scholar

10. Satoa M, Hanafusab N, Kawaguchia H, et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018; 43: 1023–103310.1159/00049082429940587Search in Google Scholar

11. Carvalho Goncalves FL, Elias RM, dos Reis L.M, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrology 2014; 15: 190.10.1186/1471-2369-15-190426542225465028Search in Google Scholar

12. Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288–293.10.1093/ndt/gfu30125248363Search in Google Scholar

13. Nowak A, Artunc F, Serra AL, et al. Sclerostin quo vadis ? – Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40: 266–276.Search in Google Scholar

14. Sooling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2018; 10(5-6): 105–115.10.1177/1759720X18775936600909429942362Search in Google Scholar

15. Brandenburg VM, Verhulst A, Babler A, et al. Sclerostin in chronic kidney disease – mineral and bone disorder think before you block it! Nephrol Dial Transplant 2018 May 24. doi: 10.1093/ndt/gfy129.10.1093/ndt/gfy12929846712Open DOISearch in Google Scholar

16. Xue-Li Du, Wen-Bo Li, and Bo-Jie Hu. (2018) Application of artificial intelligence in ophthalmology. Int J Ophthalmol 11(9): 1555–1561.Search in Google Scholar